• Outline how small molecule manufacturing is being reshaped within the broader transformation of a world-leading biopharmaceutical and vaccine manufacturer
  • Discuss how today’s pipeline and technologies are reshaping this future and how to remain agile for future changes
  • Review case studies and strategies for rapid manufacturing commercialization
  • Focus on the criticality of investing in people and how culture has to evolve as an enabler of transformation

—

Ger Carmody
SVP, Global Pharmaceutical Operations
Merck

Ger Carmody is responsible for global pharmaceutical and packaging operations comprising approximately 4000 colleagues and internal 9 manufacturing sites.  His organization supplies drug substance and drug product for Merck’s small molecule portfolio, leads the late stage development and commercialization of the small molecule pipeline as well as packages the entire human health portfolio. Ger has worked with Merck for almost 30 years, working in Europe, Asia and the US primarily in operations, technical and operational excellence roles. As well as ensuring safe, compliant supply of high quality products, current focus areas include increasing productivity through operational excellence and digital, positioning for an evolving pipeline and environmental sustainability. Ger is from Ireland, is currently based in Pennsylvania and graduated as a chemical engineer from University College Dublin.

Leave a comment